We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
+14.21%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$987M
AUM Growth
+$120M
(+14%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
6.44%
Top 10 Holdings %
Top 10 Hldgs %
5.22%
Holding
1,870
New
579
Increased
363
Reduced
419
Closed
480
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$6.71M |
| 2 |
DexCom
DXCM
|
+$6.59M |
| 3 |
X
US Steel
X
|
+$6.1M |
| 4 |
CMBT
CMB.TECH NV
CMBT
|
+$5.09M |
| 5 |
SPLK
Splunk Inc
SPLK
|
+$4.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GOOS
Canada Goose Holdings
GOOS
|
+$21.9M |
| 2 |
Constellation Brands
STZ
|
+$9.52M |
| 3 |
Lumen
LUMN
|
+$7.13M |
| 4 |
Weyerhaeuser
WY
|
+$6.3M |
| 5 |
FedEx
FDX
|
+$6.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.75% |
| 2 | Technology | 15.19% |
| 3 | Consumer Discretionary | 13.45% |
| 4 | Industrials | 12.06% |
| 5 | Financials | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BSTC
476
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $717K | 0.07% |
11,500
+4,200
| +58% | +$278K |
|
477
CONMED
CNMD
$1.47B
| $714K | 0.07% |
8,581
-3,792
| -31% | -$276K |
|
478
Gorman-Rupp
GRC
$2.21B
| $714K | 0.07% |
21,045
+5,144
| +32% | +$173K |
|
479
Lear
LEA
$8.18B
| $713K | 0.07% |
5,253
+3,420
| +187% | +$501K |
|
480
Pfizer
PFE
$153B
| $713K | 0.07% |
17,707
-10,424
| -37% | -$417K |
|
|
EVBG
481
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $713K | 0.07% |
+9,503
| New | +$621K |
|
|
CEQP
482
DELISTED
Crestwood Equity Partners LP
CEQP
| $712K | 0.07% |
+20,236
| New | +$655K |
|
483
Brink's
BCO
$4.62B
| $711K | 0.07% |
+9,429
| New | +$701K |
|
484
Tronox
TROX
$1.04B
| $711K | 0.07% |
+54,080
| New | +$572K |
|
485
World Kinect Corp
WKC
$1.86B
| $711K | 0.07% |
24,609
+12,547
| +104% | +$329K |
|
|
AEL
486
DELISTED
American Equity Investment Life Holding Company
AEL
| $711K | 0.07% |
26,310
-1,823
| -6% | -$55.2K |
|
|
AGN
487
DELISTED
Allergan plc
AGN
| $710K | 0.07% |
4,848
-40,272
| -89% | -$5.84M |
|
488
Darling Ingredients
DAR
$9.44B
| $709K | 0.07% |
+32,745
| New | +$691K |
|
489
Accenture
ACN
$108B
| $704K | 0.07% |
3,999
-16,358
| -80% | -$2.57M |
|
|
AMRN
490
Amarin Corp
AMRN
$303M
| $704K | 0.07% |
1,694
-193
| -10% | -$69.6K |
|
491
MDU Resources
MDU
$4.32B
| $704K | 0.07% |
71,672
-45,537
| -39% | -$442K |
|
|
AAT
492
American Assets Trust
AAT
$1.4B
| $701K | 0.07% |
+15,275
| New | +$661K |
|
|
LJPC
493
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $700K | 0.07% |
108,892
+70,600
| +184% | +$460K |
|
494
Phibro Animal Health
PAHC
$1.39B
| $699K | 0.07% |
21,177
+3,010
| +17% | +$93.7K |
|
495
Ross Stores
ROST
$81.9B
| $693K | 0.07% |
+7,441
| New | +$683K |
|
|
TLRD
496
DELISTED
Tailored Brands, Inc.
TLRD
| $692K | 0.07% |
88,297
+11,497
| +15% | +$136K |
|
|
Y
497
DELISTED
Alleghany Corp
Y
| $690K | 0.07% |
1,127
+286
| +34% | +$179K |
|
498
Builders FirstSource
BLDR
$8.04B
| $688K | 0.07% |
51,540
-2,920
| -5% | -$38.4K |
|
|
AAMI
499
Acadian Asset Management
AAMI
$3.19B
| $688K | 0.07% |
50,730
+39,869
| +367% | +$515K |
|
|
CMO
500
DELISTED
Capstead Mortgage Corp.
CMO
| $688K | 0.07% |
+80,093
| New | +$628K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q1 2019 Portfolio in Review
As of Q1 2019, GSA Capital Partners held 1,870 positions worth $987M, up 14% from $867M the previous quarter. Its ten largest holdings account for 5.2% of the portfolio.
GSA Capital Partners deployed $63.5M of net new capital in Q1 2019, opening 579 new positions and adding to 363 existing holdings. Its largest new stake was DexCom: 187,420 shares worth $5.58M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Lumen, an estimated $7.13M trimmed.
- GSA Capital Partners's largest Q1 2019 buy was DexCom: 187,420 shares worth $5.58M.
- GSA Capital Partners added most to Biogen in Q1 2019, an estimated $6.71M increase.
- GSA Capital Partners's biggest Q1 2019 reduction was Lumen, cutting an estimated $7.13M.
- GSA Capital Partners fully exited Canada Goose Holdings in Q1 2019, selling an estimated $21.9M.
- GSA Capital Partners's ten largest holdings make up 5.2% of its $987M portfolio in Q1 2019.
- GSA Capital Partners opened 579 new positions and closed 480 in Q1 2019.
- GSA Capital Partners's portfolio value rose 14% quarter-over-quarter to $987M.
Based on GSA Capital Partners's 13F filing for Q1 2019, filed 15 May 2019.